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Applications
Conclusions
3. Future prospects
Quizás meter en técnica una foto de equipo, + 
collage de imágenes de ESC
Also, coffee
As research on human SCNT was hindered during decades due to both sub-optimal methods and ethical concerns over oocyte sources, parallel research was successfully conducted on human induced pluripotent cells (iPS). This 7-year head start makes it unlikely for NT-
ESC to replace iPS, although the former appear to be more effective in erasing the epigenetic memory of the somatic nuclei in mice, and offer the unique possibility of treating mitochondrial related disorders. Thus, more research is required comparing how are NT-ES and
iPS cells different between them and standard ES.
In 1958 Gurdon et al reported the discovery that mature cells can be reprogrammed to become pluripotent, thus opening the door to therapeutic cloning. Since then much has been said and done regarding somatic cell nuclear transfer (SCNT). Adapting the method to
mammals supposed a big challenge, and did not happen until the cloning of Dolly in 1997. Several attempts have followed since trying to adjust protocols to primates, with poor success rates, specially in humans where reprogrammed cells usually stopped soon after reaching
the 8-cell stage. It was only as recently as of May 2013 that Tachibana et al successfully obtained for the first time derived Nuclear Transfer Stem Cells (NT-ESC), overcoming a decades-long biology hurdle.
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Figure 1: Steps in NT-ESC generation. In human, blastocyst would rarely spawn and degenerate 
due to premature oocyte activation or poor quality.
Figure 2. Tachibana et al reported increased development efficiency and quality
of the human NT-embryos following the addition of caffeine, which prevented
early activation of the oocyte. At the same time, only the caffeine group was
able to generate for the first time derived stem cell lines in Homo sapiens.
Figure 3. Enucleated 
oocyte after donor nuclei 
injection, and derived NT-
ESC in culture.
• Reproductive Cloning
Figure 4. Dolly, first cloned mammal.
The Technique
Possible uses include transgenic 
generation for disease modelling, 
preservation of  thoroughbred livestock 
and better compatibility in 
xenotransplants.
Malformations due to epigenetic 
disregulation and low efficiency rates 
pose a significant hindrance.
• Therapeutic cloning
Potential therapies for 
degenerative disorders by 
introducing autologous 
(therefore immunologically 
compatible) stem cells free 
from the disease.
Specially important in 
mitochondria related 
disorders. Figure 5. NT-ES cells are able to differentiate to virtually every cell in 
the body.
Alternatives – iPS cells
• Developed in human in 2007, they consist of  somatic cells engineered 
to express pluripotency factors.
• High propensity to form teratoma.
Possible therapies
• Wakayama et al generated domanergic
neurons from a tail biopsy in Parkinson 
model mice and cured syntomatology
after an autologous transplant. 
• In another study, Rideout
and collegues successfully 
restored immune function 
in immunodeficient mice.
Figure 8. Pluripotency
factors are normally 
inactive in somatic cells 
and can be reactivated. 
Genetic engineering of  the 
cells results in de-
differentiation and 
restored pluripotency.
Figure 7. Hematopoietic precursors are a key part in the development of  
the immune system.
Figure 6. Parkinsonian mice show progressive 
degeneration of  dopaminergic neurons.
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